Cargando…
P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430977/ http://dx.doi.org/10.1097/01.HS9.0000970428.90600.b0 |
| _version_ | 1785091089001086976 |
|---|---|
| author | Bhutani, Manisha Garfall, Alfred Uttervall, Katarina Usmani, Saad Z Karlin, Lionel Benboubker, Lotfi Nahi, Hareth San Miguel, Jesús Trancucci, Danielle Qi, Keqin Stephenson, Tara Perales-Puchalt, Alfredo Chastain, Katherine Chari, Ajai |
| author_facet | Bhutani, Manisha Garfall, Alfred Uttervall, Katarina Usmani, Saad Z Karlin, Lionel Benboubker, Lotfi Nahi, Hareth San Miguel, Jesús Trancucci, Danielle Qi, Keqin Stephenson, Tara Perales-Puchalt, Alfredo Chastain, Katherine Chari, Ajai |
| author_sort | Bhutani, Manisha |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430977 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104309772023-08-17 P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY Bhutani, Manisha Garfall, Alfred Uttervall, Katarina Usmani, Saad Z Karlin, Lionel Benboubker, Lotfi Nahi, Hareth San Miguel, Jesús Trancucci, Danielle Qi, Keqin Stephenson, Tara Perales-Puchalt, Alfredo Chastain, Katherine Chari, Ajai Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430977/ http://dx.doi.org/10.1097/01.HS9.0000970428.90600.b0 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Bhutani, Manisha Garfall, Alfred Uttervall, Katarina Usmani, Saad Z Karlin, Lionel Benboubker, Lotfi Nahi, Hareth San Miguel, Jesús Trancucci, Danielle Qi, Keqin Stephenson, Tara Perales-Puchalt, Alfredo Chastain, Katherine Chari, Ajai P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY |
| title | P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY |
| title_full | P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY |
| title_fullStr | P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY |
| title_full_unstemmed | P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY |
| title_short | P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY |
| title_sort | p881: durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majestec-1 study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430977/ http://dx.doi.org/10.1097/01.HS9.0000970428.90600.b0 |
| work_keys_str_mv | AT bhutanimanisha p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT garfallalfred p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT uttervallkatarina p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT usmanisaadz p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT karlinlionel p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT benboubkerlotfi p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT nahihareth p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT sanmigueljesus p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT trancuccidanielle p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT qikeqin p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT stephensontara p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT peralespuchaltalfredo p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT chastainkatherine p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study AT chariajai p881durabilityofresponseswithbiweeklydosingofteclistamabinpatientswithrelapsedrefractorymultiplemyelomaachievingaclinicalresponseinthemajestec1study |